The 13 most recent market catalysts affecting $ARMP, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 23, 2026
Corporate Catalyst
Bearish
Impact 65
Armata Pharmaceuticals shares are trading lower after the company announced the receipt of an additional $3.7 million in non-dilutive funds from the U.S. DoW for Phase 3 development program for AP-SA02.
The headline presents a mixed signal: non-dilutive funding is typically a positive for a company as it avoids shareholder dilution. However, the market's negative reaction suggests…
Sep 23, 2026
Corporate Catalyst
Bearish
Impact 55
Armata Pharmaceuticals Stock Slides after Pentagon Funding Fuels Phase 3 Push for Anti-Bacterial Program
Armata Pharmaceuticals announced an additional $3.7 million in non-dilutive funding from the U.S. Department of Defense, supporting its AP-SA02 program's Phase 3 work. This funding…
Sep 23, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Armata Pharmaceuticals, Maintains $15 Price Target
HC Wainwright & Co. analyst Joseph Pantginis has reaffirmed his 'Buy' rating and $15 price target for Armata Pharmaceuticals. This action signals that the analyst's outlook on the …
Sep 23, 2026
Corporate Catalyst
Bullish
Impact 65
Armata Pharmaceuticals Receives Additional $3.7M In Non-dilutive Funds From US Department Of War For Phase 3 Development Program For AP-SA02
Armata Pharmaceuticals announced an additional $3.7 million in non-dilutive funding from the U.S. Department of War (DoW) for the Phase 3 development of AP-SA02, a treatment for co…
Sep 21, 2026
Corporate Catalyst
Bullish
Impact 75
Armata Pharmaceuticals Says Lab Data Show Genetic Diversity In AP-SA02 May Enhance Killing Of Certain Staph Strains
The headline is a direct corporate catalyst for Armata Pharmaceuticals (ARMP), indicating promising lab data for their drug candidate AP-SA02. The genetic diversity enhancing 'kill…
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 92
Armata Pharmaceuticals shares are trading higher after the company announced it received FDA Breakthrough Therapy designation for AP-SA02.
The FDA Breakthrough Therapy designation is a major corporate catalyst for Armata Pharmaceuticals (ARMP). This designation is granted to drugs that treat a serious or life-threaten…
Sep 3, 2026
Corporate Catalyst
Neutral
Impact 65
Armata Pharmaceuticals Announces Journal Of Molecular Biology Publication Detailing Structure Of Ar-KM Bacteriophage Targeting Pseudomonas Aeruginosa, Pathogen Addressed By Its AP-PA02 Program
The publication in a peer-reviewed journal like the Journal of Molecular Biology lends significant scientific credibility to Armata Pharmaceuticals' AP-PA02 program. This validatio…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 92
Armata Pharmaceuticals Q2 EPS $(0.27) Beats $(0.45) Estimate, Sales $2.510M Beat $420.000K Estimate
Armata Pharmaceuticals (ARMP) announced Q2 results that significantly exceeded analyst expectations. The company reported a loss of $(0.27) per share, beating the $(0.45) estimate,…
Aug 12, 2026
Corporate Catalyst
Neutral
Impact 55
Armata Pharmaceuticals Announces Promotion Of David House To CFO
The promotion of David House to CFO at Armata Pharmaceuticals is a corporate governance event. While not immediately impacting the company's drug development pipeline or sales, a n…
Jul 20, 2026
Corporate Catalyst
Bullish
Impact 75
Why Is Armata Pharma Stock Gaining Monday?
Armata Pharmaceuticals (ARMP) reported substantial progress for its AP-SA02 drug, including submitting the complete Phase 3 protocol to the FDA and resolving all agency feedback. T…
Jul 20, 2026
Corporate Catalyst
Bullish
Impact 85
Armata Pharmaceuticals shares are trading higher after the company reported clinical, regulatory, manufacturing, and operational progress advancing AP‑SA02 toward a planned Phase 3 study in complicated Staphylococcus aureus bacteremia.
This headline represents a significant positive corporate catalyst for Armata Pharmaceuticals. The simultaneous progress across clinical, regulatory, manufacturing, and operational…
Jul 20, 2026
Corporate Catalyst
Bullish
Impact 75
Armata Announces Significant Clinical, Regulatory, Manufacturing And Operational Progress Supporting Advancement Of AP-SA02 Toward Planned Phase 3 Superiority Study For Adjunct Treatment Of Complicated Bacteremia
Armata Pharmaceuticals announced that its lead product candidate, AP-SA02, is progressing well towards a pivotal Phase 3 superiority study. The company has submitted comprehensive …
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 65
Armata Pharma Receives Agreement From FDA On Agreed Initial Pediatric Study Plan
Armata Pharmaceuticals (ARMP) has achieved a significant regulatory milestone by securing FDA agreement on an Initial Pediatric Study Plan (iPSP) for its lead bacteriophage therape…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.